secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2025-01-31T23:59:59+00:00
Accession:  0000950170-25-011430
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fractyl Health prioritizes Revita weight maintenance, Rejuva gene therapy; cuts 17% workforce
--------------------------------------------------------------------------------

- REMAIN-1 pivotal study for weight maintenance post-GLP-1 withdrawal; midpoint data analysis expected Q2 2025, full enrollment summer 2025.
- Rejuva gene therapy candidate RJVA-001 completed key preclinical studies; first-in-human studies planned H1 2025.
- Pausing Revita T2D programs (REVITALIZE-1 and German Real-World Registry) to focus resources.
- Workforce reduction of 22 employees (~17%) with estimated severance costs of $1.8M; cash runway extended into 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000095017025011430/0000950170-25-011430-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000095017025011430/guts-20250131.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-011430

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer